Treatment for vWD Gets FDA Nod
Humate-P received the nod from the FDA as a treatment for patients who have von Willebrand disease (vWD).
The biologic product is indicated for patients undergoing surgery to prevent prolonged bleeding both during surgery and post-operatively. The product previously received FDA approval to control bleeding in patients with Hemophilia A.
Effective treatment for the disease is much needed, vWD affects almost one percent of Americans and is the most common inherited bleeding disorder. The treatment will improve therapeutic options for patients with vWD by limiting potential blood loss and promotion of normal wound healing.
Related stories:
April 30, 2007 Related topics: Surgery, Hematology & Oncology